baclofen has been researched along with Algodystrophic Syndrome in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "In six women, bolus injections of 50 and 75 microg of baclofen resulted in complete or partial resolution of focal dystonia of the hands but little improvement in dystonia of the legs." | 9.09 | Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. ( Delhaas, EM; Hoff, JI; van de Beek, WJ; van Hilten, BJ; Voormolen, JH, 2000) |
| "In six women, bolus injections of 50 and 75 microg of baclofen resulted in complete or partial resolution of focal dystonia of the hands but little improvement in dystonia of the legs." | 5.09 | Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. ( Delhaas, EM; Hoff, JI; van de Beek, WJ; van Hilten, BJ; Voormolen, JH, 2000) |
| "Maternal use of the antispasmodic baclofen during pregnancy is an uncommon clinical scenario and leads to uncertainty regarding neonatal risks." | 3.72 | Intrauterine baclofen exposure: a multidisciplinary approach. ( Almeida, PG; Huttner, KM; Moran, LR; Worden, S, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lang, AE | 1 |
| Chen, R | 1 |
| Serrano-Dueñas, M | 1 |
| Moran, LR | 1 |
| Almeida, PG | 1 |
| Worden, S | 1 |
| Huttner, KM | 1 |
| Kroin, JS | 1 |
| Ali, A | 1 |
| York, M | 1 |
| Penn, RD | 1 |
| van Hilten, BJ | 1 |
| van de Beek, WJ | 1 |
| Hoff, JI | 1 |
| Voormolen, JH | 1 |
| Delhaas, EM | 1 |
| Schwartzman, RJ | 1 |
| Ross, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intrathecal (IT) Baclofen Drug Distribution Pilot Study[NCT02903823] | Phase 4 | 27 participants (Actual) | Interventional | 2016-04-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of cerebral origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cervical level 4 injection site | Thoracic level 3 injection site | Thoracic level 10 injection site | Lumbar lever 2 injection site | |
| Subjects With Max MAS Change | 8 | 7 | 3 | 3 |
"The Modified Ashworth Scale (MAS) is a 6-point scale (Standard MAS scale values: 0, 1, 1.5, 2, 3, or 4) used to evaluate spasticity based on grading muscle tone by moving joints. The MAS scores in this cohort are measured in biceps, triceps and forearm flexor muscles in upper extremities; and quadriceps, hamstrings and gastrocnemius muscles in lower extremities. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Improvement in spasticity was a reduction in MAS score by 1 point across a joint tested. Maximal MAS change is the sum of MAS score reduction in all four limbs tested.~This outcome looks at subjects with spasticity of spinal origin." (NCT02903823)
Timeframe: Baseline to 6 hours post-injection
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Cervical spine level 4 injection site | Thoracic level 3 injection site | Thoracic level 10 injection site | Lumbar level 2 injection site | |
| Subjects With MAS Change - Based on Site of Injection | 4 | 2 | 5 | 3 |
1 trial available for baclofen and Algodystrophic Syndrome
| Article | Year |
|---|---|
Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy.
Topics: Adult; Baclofen; Cross-Over Studies; Double-Blind Method; Dystonia; Female; Follow-Up Studies; GABA | 2000 |
6 other studies available for baclofen and Algodystrophic Syndrome
| Article | Year |
|---|---|
Dystonia in complex regional pain syndrome type I.
Topics: Baclofen; Causalgia; Causality; Comorbidity; Diagnosis, Differential; Dystonic Disorders; Extremitie | 2010 |
Reflex sympathetic syndrome and peripheral dystonia.
Topics: Baclofen; Diagnosis, Differential; Dystonia; Female; Humans; Muscle Relaxants, Central; Peripheral N | 2003 |
Intrauterine baclofen exposure: a multidisciplinary approach.
Topics: Analgesics, Opioid; Baclofen; Breast Feeding; Female; GABA Agonists; Humans; Infant, Newborn; Muscle | 2004 |
The distribution of medication along the spinal canal after chronic intrathecal administration.
Topics: Analgesia, Epidural; Baclofen; Endometrial Neoplasms; Female; Humans; Hydromorphone; Infusion Pumps, | 1993 |
New treatments for reflex sympathetic dystrophy.
Topics: Baclofen; Dystonia; Electric Stimulation Therapy; GABA Agonists; Humans; Reflex Sympathetic Dystroph | 2000 |
New approaches to treating a perplexing pain disorder.
Topics: Baclofen; Electric Stimulation Therapy; Humans; Injections, Spinal; Muscle Relaxants, Central; Refle | 2000 |